Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients

被引:133
作者
Seong, J
Park, HC
Han, KH
Chon, CY
机构
[1] Yonsei Univ, Coll Med, Dept Radiat Oncol, Seodamun Ku, Seoul 120752, South Korea
[2] Yonsei Univ, Coll Med, Dept Internal Med, Brain Korea Project Med Sci 21,Seodamun Ku, Seoul 120752, South Korea
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 55卷 / 02期
关键词
hepatocellular carcinoma; radiotherapy; survival; prognostic factor;
D O I
10.1016/S0360-3016(02)03929-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To analyze the treatment results and prognostic factors affecting survival in patients with unresectable hepatocellular carcinoma treated with local radiotherapy (RT). Methods and Materials: Between 1992 and 2000, 158 patients with unresectable hepatocellular carcinoma received local RT. Sixty-seven patients had an advanced UICC Stage III lesion and 91 patients had Stage IVA. The mean tumor size was 9.0 +/- 3.0 em, and liver cirrhosis was present in 142 patients. Local RT was combined with transarterial chemoembolization as primary treatment (107 patients) or as salvage after failure of repeated transarterial chemoembolization (51 patients). The mean radiation dose was 48.2 +/- 7.9 Gy in daily 1.8-Gy fractions. Results: The mean follow-up was 21.6 months after diagnosis and 14.6 months after RT. The response rate was 67.1%. The overall survival rate at 2 and 5 years was 30.5% and 9%, respectively, from the time of diagnosis (median survival time 16 months) and 19.9% and 4.7%, respectively, after RT (median survival time 10 months). On univariate analysis, tumor size (p = 0.047), the presence of portal vein thrombosis (p = 0.007), and RT dose (p = 0.001) were significant factors for survival. However, on multivariate analysis, RT dose was the only significant factor (p = 0.01). Conclusion: Local RT achieved substantial tumor regression and survival. The radiation dose was found to be a significant prognostic factor in the RT of hepatocellular carcinoma. Additional efforts for dose escalation are warranted to improve the treatment results in parallel with better protecting the nontumorous liver. (C) 2003 Elsevier Science Inc.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 50 条
  • [41] Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization
    Lee, Sangheun
    Kang, Jung Hyun
    Kim, Do Young
    Ahn, Sang Hoon
    Park, Jun Yong
    Kim, Beom Kyung
    Kim, Seung Up
    Han, Kwang-Hyub
    [J]. HEPATOLOGY INTERNATIONAL, 2017, 11 (03) : 292 - 299
  • [42] Establishment and validation of a prognostic pomogram in unresectable hepatocellular carcinoma treated with intensity modulated radiotherapy: a real world study
    Long, Meiying
    Li, Jianxu
    He, Meiling
    Qiu, Jialin
    Zhang, Ruijun
    Liu, Yingchun
    Liang, Chunfeng
    Lu, Haiyan
    Pang, Yadan
    Zhou, Hongmei
    Yu, Hongping
    Qiu, Moqin
    [J]. RADIATION ONCOLOGY, 2023, 18 (01)
  • [43] Establishment and validation of a prognostic pomogram in unresectable hepatocellular carcinoma treated with intensity modulated radiotherapy: a real world study
    Meiying Long
    Jianxu Li
    Meiling He
    Jialin Qiu
    Ruijun Zhang
    Yingchun Liu
    Chunfeng Liang
    Haiyan Lu
    Yadan Pang
    Hongmei Zhou
    Hongping Yu
    Moqin Qiu
    [J]. Radiation Oncology, 18
  • [44] Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization
    Liang, Hongyuan
    Cui, Peng
    Guo, Qiyong
    Mao, Xiaonan
    Wen, Feng
    Sun, Wei
    Shan, Ming
    Lu, Zaiming
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E331 - E341
  • [45] Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma
    Wan, Xuying
    Zhai, Xiaofeng
    Yan, Zhenlin
    Yang, Pinghua
    Li, Jun
    Wu, Dong
    Wang, Kui
    Xia, Yong
    Shen, Feng
    [J]. ONCOTARGET, 2016, 7 (50) : 83806 - 83816
  • [46] Treatment and prognostic factors in patients with hepatocellular carcinoma
    Martins, A.
    Cortez-Pinto, H.
    Marques-Vidal, P.
    Mendes, N.
    Silva, S.
    Fatela, N.
    Gloria, H.
    Marinho, R.
    Tavora, I.
    Ramalho, F.
    Carneiro de Moura, M.
    [J]. LIVER INTERNATIONAL, 2006, 26 (06) : 680 - 687
  • [47] Radiotherapy trend in elderly hepatocellular carcinoma: retrospective analysis of patients diagnosed between 2005 and 2017
    Bae, Bong Kyung
    Yu, Jeong Il
    Park, Hee Chul
    Goh, Myung Ji
    Paik, Yong-Han
    [J]. RADIATION ONCOLOGY JOURNAL, 2023, 41 (02): : 98 - 107
  • [48] Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study
    Guo, Chengxiang
    Du, Weiran
    Chen, Yiwen
    Xiao, Wenbo
    Sun, Ke
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Yu, Jun
    Que, Risheng
    Xue, Xing
    Bai, Xueli
    Liang, Tingbo
    [J]. CANCER MEDICINE, 2025, 14 (03):
  • [49] Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma
    Lin, Haimin
    Wu, Huiyong
    Cong, Ning
    Liu, Bo
    Liu, Chengxin
    Han, Dali
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [50] Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
    Chen, Yen-Yang
    Wang, Chih-Chi
    Liu, Yueh-Wei
    Li, Wei-Feng
    Chen, Yen-Hao
    [J]. PEERJ, 2020, 8